Determining whether SCYNEXIS (NASDAQ: SCYX) is a buy or sell depends heavily on your individual risk tolerance, investment horizon, and strategy regarding clinical-stage biotechnology equities. While certain equity analysts highlight positive long-term therapeutic potential for its antifungal portfolio, developmental biopharmaceuticals carry high volatility, binary clinical trial risks, and potential dilution. Consulting a certified financial advisor is recommended before making trades.